Page 9 - Biocon

Drug controller approves Biocon's psoriasis drug for emergency Covid-19 use

The firm presented the phase II clinical trial results to the drug regulator which were deliberated upon by the Subject Expert Committee of the DCGI's office

Pharma shares gain; Biocon, Granules hit record highs, Sun Pharma up 3%

At 10:27 am, Nifty Pharma index was up 1.5 per cent, as compared to 0.22 per cent decline in the benchmark Nifty50 index

Biocon to invest $200 million on capital expenditure in current fiscal

Biocon CEO and Managing Director Siddharth Mittal said the investment would be split across small molecules and biosimilar verticals

Biocon ties up with DKSH to distribute 7 products in Singapore, Thailand

Under the terms of the pact, DKSH will gain an exclusive license to register and commercialise the seven generic formulations from various therapeutic areas

Biocon gets a shot in the arm with FDA approval for insulin glargine

The drug will be major contributor in the firm's bid to reach $1 billion revenue target by FY22, says biologics CEO Hamacher

Biocon's Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020

Shaw was picked from among 46 award winners from 41 countries and territories vying for the global title

Biocon MD Kiran Mazumdar-Shaw named EY World Entrepreneur Of The Year

The Biocon MD was picked from among 46 nominations from 41 countries

Biocon rallies 6%, hits record high on favourable ruling from US PTAB

Biocon's partner Mylan received a favourable ruling from U.S. Patent and Trademark Appeal Board (PTAB) on Sanofi's four device patents for Lantus SoloSTAR.

Biocon gets DCGI nod for CytoSorb device to treat Covid-19 patients

CytoSorb therapy reduces cytokine storm and the inflammatory response in Covid-19 patients through blood purification so that injury to organs may be mitigated or prevented

Logging in with facemasks: Offices look different as staff returns to work

Office life in these cities resumed on Monday, albeit cautiously and with full knowledge of the need to maintain social distancing.

Will invest Rs 2k cr in small molecules segment in 3-4 yrs: Biocon CEO & MD

In a Q&A, Biocon CEO and MD Siddharth Mittal explains why he believes his company is on track to achieve the $1 billion revenue target from the segment by 2022

MARKET WRAP: Indices end flat, Sensex slips 25 pts; financials, autos fall

All that happened in the markets today

Biocon shares slump over 4% as profit declines 42% in March quarter

The company's revenue, however, saw a muted growth of 6 per cent as compared to Q4 of FY19

Market Ahead, May 11: Top factors that could guide markets this week

Around 50 companies including the likes of Maruti Suzuki, Nestle, Dr Reddy's Labs, Biocon, and Bandhan Bank are scheduled to announce their March quarter results.

Mumbai docs try Biocon and Roche's biologic drugs on critical Covid cases

Two repurposed drugs for rheumatoid arthritis and psoriasis are being tried on over 100 patients in Mumbai

MSCI India rebalancing to stoke FPI inflows to the tune of Rs 1,900 cr

The rebalancing is scheduled to take place on May 12 and the changes will become effective from June 1

India Inc wants govt to shift focus to economy amid Covid-19 outbreak

CEOs warn of economic depression, say need to work within new normal

Biocon gains 5% as two Bengaluru facilities receive EIR from USFDA

The stock was trading close to its all-time high level of Rs 359, touched in September 2018

Biocon, Mylan launch Fulphila, a biosimilar Pegfilgrastim in Australia

CEO of Biocon Biologics, Dr Christiane Hamacher said, Fulphila, co-developed by Biocon Biologics and Mylan, is the third biosimilar to be commercialised in Australia

Malaysia plant boosts Biocon prospects in US and other key markets

Firm seen benefiting from operating leverage, biologic sales by FY22